Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Official Positions
84%
Vertebral Fracture Assessment
84%
Bone Disease
84%
Vertebral Fracture
84%
Nitrogen-containing Bisphosphonates
84%
Bone Turnover
42%
Bone Mineral Density
42%
Alendronate
42%
Osteoporosis Treatment
42%
Osteopenia
42%
Bone Metabolism
42%
Phosphate Metabolism
42%
Hypercalcemia
42%
Estrogen Status
42%
Osteoporosis Diagnosis
42%
Paget's Disease of Bone
42%
Menopause
42%
Hypocalcemia
42%
Atypical Femur Fracture
31%
Osteonecrosis of the Jaw
31%
Osteoporotic Fractures
21%
Spine Imaging
21%
Low Radiation
21%
Classification Strategy
21%
Historical Height Loss
21%
Quality of Life
21%
Prednisone
21%
Glucocorticoid Therapy
21%
Diagnostic Classification
21%
Treatment Strategy
21%
High Risk
21%
Lateral Spine
21%
Dual-energy X-ray Absorptiometry
21%
Diagnostic Intervention
21%
Fracture Risk
21%
Significant Risk Factors
21%
High Mortality
21%
High Morbidity
21%
Most Common Form
21%
Relative Competitiveness
21%
Unidentified Patient
12%
Differential Responsiveness
10%
Prescription Drugs
10%
Differentially Expressed
10%
Poor Outcome
10%
Cellular Factors
10%
Coding Variants
10%
Cell Viability
10%
Geranylgeranyl Diphosphate Synthase
10%
Osteoclast Function
10%
Medicine and Dentistry
Locally Advanced Breast Cancer
84%
Metastatic Carcinoma
84%
Zoledronic Acid
84%
Ophthalmology
84%
Urology
84%
General Surgery
84%
Otorhinolaryngology
84%
Neurosurgery
84%
Orthopedic Surgery
84%
Surgical Training
84%
Bone Disease
84%
Bone Turnover
42%
Estrogen
42%
Bone Density
42%
Bone Remodeling
42%
Hypocalcaemia
42%
Paget Bone Disease
42%
Osteopenia
42%
Osteoporosis
42%
Diseases
42%
Hypercalcaemia
42%
Phosphate Metabolism
42%
Breast Cancer
19%
Disease Exacerbation
12%
Docetaxel
12%
Epirubicin
12%
Bisphosphonate
6%
Disease Free Survival
6%
Osteolysis
6%
Infection
6%
Heart Function
6%
Neoadjuvant Chemotherapy
6%
Bone Necrosis
6%
Thrombosis
6%
Diarrhea
6%
Clinical Stage
6%
Oncology
6%
Liver Function
6%
Kidney Function
6%
Chemotherapy
6%
Pharmacology, Toxicology and Pharmaceutical Science
Bisphosphonic Acid Derivative
100%
Menatetrenone
84%
Farnoquinone
84%
Osteocalcin
84%
Zoledronic Acid
84%
Breast Cancer
84%
Fragility Fracture
18%
Disease Exacerbation
12%
Chemotherapy Regimens
12%
Docetaxel
12%
Epirubicin
12%
Alendronic Acid
12%
Femur Shaft Fracture
12%
Tetracycline
12%
Clinical Feature
12%
Prevalence
12%
Vitamin K Group
9%
Side Effect
9%
Borderline State
9%
Prospective Cohort Study
9%
Compression Fracture
9%
Disease Free Survival
6%
Diarrhea
6%
Infection
6%
Thrombosis
6%
Bone Necrosis
6%